Clinical Trial Search

Phase 3 N=227 A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate

Diabetes Mellitus, Type 2

Primary: HbA1c Change From Baseline at Week 18 (Interim Analysis) — 0.14; -0.44 percent — p=<0.0001

Boehringer Ingelheim Results Oct 2011 1.8% serious AE View details

Phase 3 N=61 Effect of Stopping Risedronate After Long Term Treatment on Bone Turnover

Postmenopausal Women With Osteoporosis

Primary: Mean Percent Change in Lumbar Spine Bone Mineral Density (BMD) From Core Study Baseline, Month 6, Intention to Treat (ITT) Population — 6.2217; 12.7784 Percent Change

Warner Chilcott Results Oct 2011 3.3% serious AE View details

Phase 3 N=629 Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)

Clostridium Infections · Diarrhea

Primary: Cure Rate at End of Therapy — 85.7; 88.2 Percentage of Participants

Optimer Pharmaceuticals LLC, a subsidiary of… Results Oct 2011 24.6% serious AE View details

Phase 3 N=340 Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)

Attention-Deficit/Hyperactivity Disorder

Primary: Change From Baseline in Attention-Deficit/Hyperactivity Disorder-Rating Scale-IV (ADHD-RS-IV) Total Score at Week 8 - Last Observation Carried Forward (LOCF) — -10.6…

Shire Results Oct 2011 1.1% serious AE View details

Phase 3 N=112 A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)

Juvenile Idiopathic Arthritis

Primary: Part I: Percentage of Participants With ≥30% Improvement in Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) Core Set and Absence of Fever…

Hoffmann-La Roche Results Oct 2011 42.9% serious AE View details

Phase 3 N=1,196 Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in Chronic Obstructive Pulmonary Disease (COPD) (Study P04230AM4)(COMPLETED)

Chronic Obstructive Pulmonary Disease (COPD)

Primary: Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 13 in Forced Expiratory Volume (Liters) in 1 Second (FEV1) — 1.189…

Organon and Co Results Oct 2011 11.1% serious AE View details

Phase 3 N=306 Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy

Seizures

Primary: Percent Change in the 28-day Total Partial Seizure (PS) Frequency From Baseline (BL) to the End of the Double-blind (DB) Phase (Titration and Maintenance Phases)…

GlaxoSmithKline Results Oct 2011 7.3% serious AE View details

Phase 3 N=746 Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04073AM1)(COMPLETED)

Asthma

Primary: Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1) — 3.94…

Organon and Co Results Oct 2011 0.8% serious AE View details

Phase 3 N=57 Lamotrigine for Symptoms of Geriatric Bipolar Depression

Bipolar Disorder · Depression, Bipolar

Primary: Assessment of Change in Depressive Symptoms From Baseline on the Montgomery Asberg Depression Rating Scale (MADRS) — -15.5 units on a scale — p=<.01

University Hospitals Cleveland Medical Center Results Oct 2011 3.5% serious AE View details

Phase 3 N=660 Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy

Epilepsy, Partial

Primary: Percentage of Seizure-free Participants (Responders) During Efficacy Assessment Phase — 51.6; 67.9 percentage of participants

Pfizer's Upjohn has merged with Mylan to form… Results Oct 2011 11.5% serious AE View details

Phase 3 N=1,579 Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis

Staphylococcal Sepsis

Primary: The Number of Participants With Staphylococcal Sepsis From Study Days 0 to 35. — 85; 79 Participants

Biosynexus Incorporated Results Oct 2011 35.7% serious AE View details

Phase 3 N=347 Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

Coronary Artery Disease (CAD)

Primary: Change in Number of Reversible Defects — 0.67; 1.01; 1.00; 0.80 Reversible Defects — p=<0.001

Astellas Pharma Inc Results Oct 2011 1.5% serious AE View details

Phase 3 N=560 Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyalgia.

Fibromyalgia

Primary: Number of Subjects Reporting Adverse Events — 498 Participants

Jazz Pharmaceuticals Results Oct 2011 3.4% serious AE View details

Phase 3 N=416 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Overactive Bladder

Primary: Change From Baseline in Number of Weekly Episodes of Urinary Incontinence — 31.1; 32.3; 28.3; -22.7 Number of Weekly Episodes

Allergan Results Oct 2011 18.7% serious AE View details

Phase 3 N=275 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Overactive Bladder

Primary: Change From Baseline in Number of Weekly Episodes of Urinary Incontinence — 31.2; 32.5; 36.7; -19.4 Number of Weekly Episodes

Allergan Results Oct 2011 21.5% serious AE View details